Overview

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Status:
Active, not recruiting

Trial end date:
2025-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity.

Phase:

Phase 3

Details

Lead Sponsor:

Alexion Pharmaceuticals

Treatments:

Eculizumab